Table 2 Demographics and [11C]Cimbi-36 radioligand injection parameters at baseline and intervention PET scans

From: Measuring endogenous changes in serotonergic neurotransmission with [11C]Cimbi-36 positron emission tomography in humans

 

Placebo

Citalopram/Pindolol

ATD

Number of subjects

8 (4 males)

8 (4 males)

8 (4 males)

Age (years)

22.0 ± 2.5

21.9 ± 2.0

22.3 ± 3.2

Body Mass Index (kg/m2)

23.6 ± 2.5

23.9 ± 1.9

22.6 ± 1.9

Interscan interval (days)

30.6 ± 15.5

22.4 ± 2.8

27.6 ± 17.1

 

Baseline

Intervention

Baseline

Intervention

Baseline

Interventiona

Injected dose (MBq)

509 ± 95

581 ± 27

477 ± 142

574 ± 37

554 ± 54

554 ± 52

Injected mass (µg)

0.9 ± 0.5

0.9 ± 0.5

0.9 ± 0.6

0.7 ± 0.5

0.9 ± 0.5

1.0 ± 0.4

Free fraction in plasma, fP (%)

2.7 ± 0.4

3.7 ± 0.5

2.9 ± 0.5

3.4 ± 0.8

3.0 ± 0.5

3.0 ± 0.8

  1. Values represent mean ± standard deviation
  2. a One female subject excluded due to adverse reaction during the baseline scan
Back to article page